ARGNF
Price
$833.50
Change
+$33.50 (+4.19%)
Updated
Oct 6 closing price
Capitalization
51.08B
Intraday Buy/Sell Signals
IMVT
Price
$19.29
Change
+$0.07 (+0.36%)
Updated
Oct 21, 11:36 AM (EDT)
Capitalization
3.35B
10 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

ARGNF vs IMVT

Header iconARGNF vs IMVT Comparison
Open Charts ARGNF vs IMVTBanner chart's image
Argen X
Price$833.50
Change+$33.50 (+4.19%)
Volume$3
Capitalization51.08B
Immunovant
Price$19.29
Change+$0.07 (+0.36%)
Volume$644
Capitalization3.35B
ARGNF vs IMVT Comparison Chart in %
ARGNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARGNF vs. IMVT commentary
Oct 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGNF is a Hold and IMVT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 21, 2025
Stock price -- (ARGNF: $833.50 vs. IMVT: $19.22)
Brand notoriety: ARGNF and IMVT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARGNF: 88% vs. IMVT: 161%
Market capitalization -- ARGNF: $51.08B vs. IMVT: $3.35B
ARGNF [@Biotechnology] is valued at $51.08B. IMVT’s [@Biotechnology] market capitalization is $3.35B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARGNF’s FA Score shows that 1 FA rating(s) are green whileIMVT’s FA Score has 0 green FA rating(s).

  • ARGNF’s FA Score: 1 green, 4 red.
  • IMVT’s FA Score: 0 green, 5 red.
According to our system of comparison, ARGNF is a better buy in the long-term than IMVT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARGNF’s TA Score shows that 1 TA indicator(s) are bullish while IMVT’s TA Score has 6 bullish TA indicator(s).

  • ARGNF’s TA Score: 1 bullish, 2 bearish.
  • IMVT’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, IMVT is a better buy in the short-term than ARGNF.

Price Growth

ARGNF (@Biotechnology) experienced а 0.00% price change this week, while IMVT (@Biotechnology) price change was +10.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.62%. For the same industry, the average monthly price growth was +17.01%, and the average quarterly price growth was +69.82%.

Reported Earning Dates

IMVT is expected to report earnings on Oct 31, 2025.

Industries' Descriptions

@Biotechnology (+3.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARGNF($51.1B) has a higher market cap than IMVT($3.35B). ARGNF YTD gains are higher at: 27.769 vs. IMVT (-22.406). ARGNF has higher annual earnings (EBITDA): 690M vs. IMVT (-470.69M). ARGNF has more cash in the bank: 3.93B vs. IMVT (599M). IMVT has less debt than ARGNF: IMVT (98K) vs ARGNF (43.2M). ARGNF has higher revenues than IMVT: ARGNF (3.05B) vs IMVT (0).
ARGNFIMVTARGNF / IMVT
Capitalization51.1B3.35B1,525%
EBITDA690M-470.69M-147%
Gain YTD27.769-22.406-124%
P/E Ratio42.42N/A-
Revenue3.05B0-
Total Cash3.93B599M656%
Total Debt43.2M98K44,082%
FUNDAMENTALS RATINGS
ARGNF vs IMVT: Fundamental Ratings
ARGNF
IMVT
OUTLOOK RATING
1..100
4420
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
37
Fair valued
PROFIT vs RISK RATING
1..100
7100
SMR RATING
1..100
3998
PRICE GROWTH RATING
1..100
4152
P/E GROWTH RATING
1..100
78100
SEASONALITY SCORE
1..100
507

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMVT's Valuation (37) in the null industry is somewhat better than the same rating for ARGNF (81). This means that IMVT’s stock grew somewhat faster than ARGNF’s over the last 12 months.

ARGNF's Profit vs Risk Rating (7) in the null industry is significantly better than the same rating for IMVT (100). This means that ARGNF’s stock grew significantly faster than IMVT’s over the last 12 months.

ARGNF's SMR Rating (39) in the null industry is somewhat better than the same rating for IMVT (98). This means that ARGNF’s stock grew somewhat faster than IMVT’s over the last 12 months.

ARGNF's Price Growth Rating (41) in the null industry is in the same range as IMVT (52). This means that ARGNF’s stock grew similarly to IMVT’s over the last 12 months.

ARGNF's P/E Growth Rating (78) in the null industry is in the same range as IMVT (100). This means that ARGNF’s stock grew similarly to IMVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARGNFIMVT
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
29%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
N/A
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
16%
Bullish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
33%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
31%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
N/A
Bullish Trend 1 day ago
75%
Declines
ODDS (%)
N/A
Bearish Trend 14 days ago
83%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
87%
Aroon
ODDS (%)
Bullish Trend 1 day ago
10%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
ARGNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JSVSX15.920.23
+1.47%
Janus Henderson Small-Mid Cap Value S
TCEMX13.58N/A
N/A
Templeton Emerging Markets Small Cap C
APGYX123.26N/A
N/A
AB Large Cap Growth Advisor
GSAKX20.50N/A
N/A
Goldman Sachs International Eq Inc A
CCCNX6.27N/A
N/A
Center Coast Brookfield Midstream Foc I

ARGNF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARGNF has been loosely correlated with ARGX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGNF jumps, then ARGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARGNF
1D Price
Change %
ARGNF100%
N/A
ARGX - ARGNF
54%
Loosely correlated
+0.69%
MNKD - ARGNF
30%
Poorly correlated
+0.37%
TNXP - ARGNF
25%
Poorly correlated
+6.55%
ROIV - ARGNF
24%
Poorly correlated
+2.78%
IMVT - ARGNF
24%
Poorly correlated
+9.77%
More

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with IDYA. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
+9.77%
IDYA - IMVT
54%
Loosely correlated
+4.27%
ROIV - IMVT
53%
Loosely correlated
+2.78%
CLDX - IMVT
49%
Loosely correlated
+3.13%
DNLI - IMVT
49%
Loosely correlated
+3.54%
NUVL - IMVT
48%
Loosely correlated
+5.89%
More